Aclaris Therapeutics宣布其2a期临床试验取得积极结果

老虎资讯综合

30 Jul

7月30日，Aclaris Therapeutics股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。

这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。研究涉及14名患者，他们接受了ATI-2138的低剂量治疗，这是一种选择性口服抑制剂，靶向白细胞介素-2诱导性T细胞激酶(ITK)和Janus激酶3(JAK3)。

结果显示，湿疹面积和严重程度指数(EASI)有所改善，并且按照峰值瘙痒数字评分量表测量，经历瘙痒严重程度减轻的患者百分比也有所增加。该公司强调，这些低剂量的疗效结果与已获批的JAK和IL-4/13抑制剂相当，但可能具有更好的耐受性。

Aclaris首席执行官Neal Walker博士表示："这些2a期试验结果是我们ITK项目的重大成就，它证实了该机制并佐证了我们在下一代ITK选择性化合物上的工作。"

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1190434871"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1190434871\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1190434871?lang=en_US&edition=fundamental","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","is_english":false,"pubTime":"2025-07-30 06:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190434871","market":"us","top_or_hot":-1,"title":"Aclaris Therapeutics宣布其2a期临床试验取得积极结果","media":"老虎资讯综合","content":"<html><head></head><body><p>7月30日，<a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a>股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8db330fdafa51484608070bb94785d01\" tg-width=\"865\" tg-height=\"829\"/></p><p style=\"text-align: start;\">这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。研究涉及14名患者，他们接受了ATI-2138的低剂量治疗，这是一种选择性口服抑制剂，靶向白细胞介素-2诱导性T细胞激酶(ITK)和Janus激酶3(JAK3)。</p><p style=\"text-align: start;\">结果显示，湿疹面积和严重程度指数(EASI)有所改善，并且按照峰值瘙痒数字评分量表测量，经历瘙痒严重程度减轻的患者百分比也有所增加。该公司强调，这些低剂量的疗效结果与已获批的JAK和IL-4/13抑制剂相当，但可能具有更好的耐受性。</p><p style=\"text-align: start;\">Aclaris首席执行官Neal Walker博士表示：&#34;这些2a期试验结果是我们ITK项目的重大成就，它证实了该机制并佐证了我们在下一代ITK选择性化合物上的工作。&#34;</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics宣布其2a期临床试验取得积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics宣布其2a期临床试验取得积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-07-30 06:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>7月30日，<a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a>股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8db330fdafa51484608070bb94785d01\" tg-width=\"865\" tg-height=\"829\"/></p><p style=\"text-align: start;\">这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。研究涉及14名患者，他们接受了ATI-2138的低剂量治疗，这是一种选择性口服抑制剂，靶向白细胞介素-2诱导性T细胞激酶(ITK)和Janus激酶3(JAK3)。</p><p style=\"text-align: start;\">结果显示，湿疹面积和严重程度指数(EASI)有所改善，并且按照峰值瘙痒数字评分量表测量，经历瘙痒严重程度减轻的患者百分比也有所增加。该公司强调，这些低剂量的疗效结果与已获批的JAK和IL-4/13抑制剂相当，但可能具有更好的耐受性。</p><p style=\"text-align: start;\">Aclaris首席执行官Neal Walker博士表示：&#34;这些2a期试验结果是我们ITK项目的重大成就，它证实了该机制并佐证了我们在下一代ITK选择性化合物上的工作。&#34;</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1190434871","we_media_id":"102","thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190434871","pubTimestamp":1753829466,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"老虎资讯综合","introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"7月30日，$Aclaris Therapeutics$股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。Aclaris首席执行官Neal Walker博士表示：\"这些2a期试验结果是我们ITK项目的重大成就，它证实了该机制并佐证了我们在下一代ITK选择性化合物上的工作。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","BK1576":"医药外包概念","ACRS":"Aclaris Therapeutics","BK4539":"次新股","BK1583":"高瓴概念","BK4139":"生物科技","BK1141":"生命科学工具和服务"},"translate_title":"Aclaris Therapeutics Announces Positive Results from Its Phase 2a Clinical Trial","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/fb862e18061416b6303c9ab615403655","symbols_score_info":{"ACRS":1},"content_text":"7月30日，Aclaris Therapeutics股价在宣布其ATI-2138治疗中度至重度特应性皮炎的2a期临床试验取得积极顶线结果后，盘后交易中飙升20%。这家临床阶段生物制药公司报告称，该试验达到了其目标，展示了良好的耐受性和临床上显著的疾病严重程度改善。研究涉及14名患者，他们接受了ATI-2138的低剂量治疗，这是一种选择性口服抑制剂，靶向白细胞介素-2诱导性T细胞激酶(ITK)和Janus激酶3(JAK3)。结果显示，湿疹面积和严重程度指数(EASI)有所改善，并且按照峰值瘙痒数字评分量表测量，经历瘙痒严重程度减轻的患者百分比也有所增加。该公司强调，这些低剂量的疗效结果与已获批的JAK和IL-4/13抑制剂相当，但可能具有更好的耐受性。Aclaris首席执行官Neal Walker博士表示：\"这些2a期试验结果是我们ITK项目的重大成就，它证实了该机制并佐证了我们在下一代ITK选择性化合物上的工作。\"","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}